Post Profile






Mylan, U.S. finalize $465 million EpiPen settlement

BOSTON (Reuters) - Mylan NV has finalized a $465 million settlement with the U.S. Justice Department resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.
read more

share

Related Posts


Blink, and you would've missed that another agency is investigating the maker of EpiPen (MYL)

Business & Finance : Business Insider: Money Game

On Friday, Mylan, the maker of EpiPen, announced that it had reached a $465 million settlement with the US Department of Justice for overcharging the government for the life-saving drug. Mylan will not admit to wrongdoing. The settl...

EpiPen Maker To Finally Pay $465 Million For Ripping Off US Taxpayers

Technology / Gadgets : Gizmodo Australia

Photo. Getty EpiPen manufacturer Mylan has been involved in a contentious legal case over its overcharging of the US government. On Thursday, the US Department of Justice finalised its settlement with Mylan, which will pay $US465 ($...

The maker of EpiPen has agreed to pay the government $465 million after allegedly overcharging for the medicine

Business & Finance : Business Insider: Money Game

Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm. Mylan had unde...

EpiPen maker finalizes settlement for government overcharges

Politics / US Politics : Washington Watch

EpiPen maker Mylan has finalized a $465 million federal agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade — charges brought after rival Sanofi filed … Click to Continue »

Mylan to pay $465 million over EpiPen Medicaid rebate dispute

Health : Reuters: Health

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle the question of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.

Comments


Copyright © 2016 Regator, LLC